Publications by Gunnveig Grødeland

45 publications found

Publications 2024

1. Alirezaylavasani A, Egner IM, Dahl B, Chopra A, de Matos Kasahara T, Goll GL, Jahnsen J, Grødeland G, Vaage JT, Lund-Johansen F, Holter JC, Halvorsen B, Jørgensen KK, Munthe LA, Kared H (2024)
   Deficient SARS-CoV-2 hybrid immunity during inflammatory bowel disease
   Clin Immunol, 271, 110404 (in press)
   DOI 10.1016/j.clim.2024.110404, PubMed 39645159
2. Hinke DM, Anderson AM, Katta K, Laursen MF, Tesfaye DY, Werninghaus IC, Angeletti D, Grødeland G, Bogen B, Braathen R (2024)
   Applying valency-based immuno-selection to generate broadly cross-reactive antibodies against influenza hemagglutinins
   Nat Commun, 15 (1), 850
   DOI 10.1038/s41467-024-44889-w, PubMed 38346952
3. Wolf AS, Bjørlykke KH, Ørbo HS, Bhandari S, Solum G, Kjønstad IF, Jyssum I, Nygaard UC, Kristoffersen AB, Christensen IE, Josefsson SE, Lund KP, Chopra A, Osen JR, Chaban V, Tveter AT, Sexton J, Kvien TK, Jahnsen J, Haavardsholm EA, Grødeland G, Vaage JT, Provan SA, Kared H, Lund-Johansen F et al. (2024)
   T cell responses to repeated SARS-CoV-2 vaccination and breakthrough infections in patients on TNF inhibitor treatment: a prospective cohort study
   EBioMedicine, 108, 105317
   DOI 10.1016/j.ebiom.2024.105317, PubMed 39260039
4. Ørbo HS, Bjørlykke KH, Sexton J, Jyssum I, Tveter AT, Christensen IE, Mjaaland S, Kvien TK, Grødeland G, Kro GB, Jahnsen J, Haavardsholm EA, Munthe LA, Provan SA, Vaage JT, Goll GL, Jørgensen KK, Syversen SW (2024)
   Incidence and outcome of COVID-19 following vaccine and hybrid immunity in patients on immunosuppressive therapy: identification of protective post-immunisation anti-RBD antibody levels in a prospective cohort study
   RMD Open, 10 (2)
   DOI 10.1136/rmdopen-2023-003545, PubMed 38599653
5. Ørbo HS, de Matos Kasahara T, Wolf AS, Bjørlykke KH, Sexton J, Jyssum I, Tveter AT, Solum G, Kjønstad IF, Bhandari S, Christensen IE, Kvien TK, Lind A, Kared H, Jahnsen J, Haavardsholm EA, Munthe LA, Provan SA, Vaage JT, Mjaaland S, Syversen SW, Jørgensen KK, Grødeland G, Goll GL (2024)
   Humoral and cellular responses to a fifth bivalent SARS-CoV-2 vaccine dose in patients with immune-mediated inflammatory diseases on tumour necrosis factor inhibitors: a prospective cohort study
   Lancet Reg Health Eur, 48, 101121
   DOI 10.1016/j.lanepe.2024.101121, PubMed 39624496

Publications 2023

1. Kared H, Alirezaylavasani A, Lund KP, Chopra A, Tietze L, de Matos Kasahara T, Goll GL, Grødeland G, Kaarbø M, Reisæter AV, Hovd M, Heldal K, Vaage JT, Lund-Johansen F, Midtvedt K, Åsberg A, Munthe LA (2023)
   Hybrid and SARS-CoV-2-vaccine immunity in kidney transplant recipients
   EBioMedicine, 97, 104833
   DOI 10.1016/j.ebiom.2023.104833, PubMed 37844534
2. Tjärnhage E, Brown D, Bogen B, Andersen TK, Grødeland G (2023)
   Trimeric, APC-Targeted Subunit Vaccines Protect Mice against Seasonal and Pandemic Influenza
   J Virol, 97 (2), e0169422
   DOI 10.1128/jvi.01694-22, PubMed 36719241
3. Tran TT, Vaage EB, Mehta A, Chopra A, Tietze L, Kolderup A, Anthi A, König M, Nygaard G, Lind A, Müller F, Nissen-Meyer LS, Magnus P, Trogstad L, Mjaaland S, Søraas A, Midtvedt K, Åsberg A, Barratt-Due A, Medhus AW, Høivik ML, Lundin K, Karlsen RF, Dahle R, Danielsson K et al. (2023)
   Author Correction: Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants
   NPJ Vaccines, 8 (1), 4
   DOI 10.1038/s41541-023-00600-6, PubMed 36697432

Publications 2022

1. Bjørlykke KH, Ørbo HS, Tveter AT, Jyssum I, Sexton J, Tran TT, Christensen IE, Kro GB, Kvien TK, Jahnsen J, Munthe LA, Chopra A, Warren DJ, Mjaaland S, Haavardsholm EA, Grødeland G, Provan SA, Vaage JT, Syversen SW, Goll GL, Jørgensen KK (2022)
   Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study
   Lancet Rheumatol, 5 (1), e36-e46
   DOI 10.1016/S2665-9913(22)00330-7, PubMed 36415604
2. Brinch SA, Amundsen-Isaksen E, Espada S, Hammarström C, Aizenshtadt A, Olsen PA, Holmen L, Høyem M, Scholz H, Grødeland G, Sowa ST, Galera-Prat A, Lehtiö L, Meerts IATM, Leenders RGG, Wegert A, Krauss S, Waaler J (2022)
   The Tankyrase Inhibitor OM-153 Demonstrates Antitumor Efficacy and a Therapeutic Window in Mouse Models
   Cancer Res Commun, 2 (4), 233-245
   DOI 10.1158/2767-9764.CRC-22-0027, PubMed 36873622
3. Christensen IE, Jyssum I, Tveter AT, Sexton J, Tran TT, Mjaaland S, Kro GB, Kvien TK, Warren DJ, Jahnsen J, Munthe LA, Haavardsholm EA, Vaage JT, Grødeland G, Lund-Johansen F, Jørgensen KK, Syversen SW, Goll GL, Provan SA (2022)
   The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls-a prospective cohort study
   BMC Med, 20 (1), 378
   DOI 10.1186/s12916-022-02587-8, PubMed 36199139
4. Hinke DM, Andersen TK, Gopalakrishnan RP, Skullerud LM, Werninghaus IC, Grødeland G, Fossum E, Braathen R, Bogen B (2022)
   Antigen bivalency of antigen-presenting cell-targeted vaccines increases B cell responses
   Cell Rep, 39 (9), 110901
   DOI 10.1016/j.celrep.2022.110901, PubMed 35649357
5. Keresztes G, Baer M, Alfenito MR, Verwoerd TC, Kovalchuk A, Wiebe MG, Andersen TK, Saloheimo M, Tchelet R, Kensinger R, Grødeland G, Emalfarb M (2022)
   The Highly Productive Thermothelomyces heterothallica C1 Expression System as a Host for Rapid Development of Influenza Vaccines
   Vaccines (Basel), 10 (2)
   DOI 10.3390/vaccines10020148, PubMed 35214607
6. Mahalingam S, Grødeland G (2022)
   [Menstrual abnormalities after COVID-19 vaccination]
   Tidsskr Nor Laegeforen, 142 (9)
   DOI 10.4045/tidsskr.22.0217, PubMed 35699538
7. Syversen SW, Jyssum I, Tveter AT, Sexton J, Christensen IE, Tran TT, Bjørlykke KH, Mjaaland S, Warren DJ, Kvien TK, Chopra A, Kro GB, Jahnsen J, Munthe LA, Haavardsholm EA, Grødeland G, Vaage JT, Provan SA, Jørgensen KK, Goll GL (2022)
   Immunogenicity and safety of a three-dose SARS-CoV-2 vaccination strategy in patients with immune-mediated inflammatory diseases on immunosuppressive therapy
   RMD Open, 8 (2)
   DOI 10.1136/rmdopen-2022-002417, PubMed 36328399
8. Syversen SW, Jyssum I, Tveter AT, Tran TT, Sexton J, Provan SA, Mjaaland S, Warren DJ, Kvien TK, Grødeland G, Nissen-Meyer LSH, Ricanek P, Chopra A, Andersson AM, Kro GB, Jahnsen J, Munthe LA, Haavardsholm EA, Vaage JT, Lund-Johansen F, Jørgensen KK, Goll GL (2022)
   Immunogenicity and Safety of Standard and Third-Dose SARS-CoV-2 Vaccination in Patients Receiving Immunosuppressive Therapy
   Arthritis Rheumatol, 74 (8), 1321-1332
   DOI 10.1002/art.42153, PubMed 35507355
9. Søraas A, Grødeland G, Granerud BK, Ueland T, Lind A, Fevang B, Murphy SL, Huse C, Nygaard AB, Steffensen AK, Al-Baldawi H, Holberg-Petersen M, Andresen LL, Ågnes C, Ranheim T, Schanke Y, Istre M, Dahl JA, Chopra A, Dudman S, Kaarbø M, Andersen JT, Vaage EB, Tran TT, Vaage JT et al. (2022)
   Breakthrough infections with the omicron and delta variants of SARS-CoV-2 result in similar re-activation of vaccine-induced immunity
   Front Immunol, 13, 964525
   DOI 10.3389/fimmu.2022.964525, PubMed 36159859
10. Tran TT, Vaage EB, Mehta A, Chopra A, Tietze L, Kolderup A, Anthi A, König M, Nygaard G, Lind A, Müller F, Nissen-Meyer LS, Magnus P, Trogstad L, Mjaaland S, Søraas A, Midtvedt K, Åsberg A, Barratt-Due A, Medhus AW, Høivik ML, Lundin K, Karlsen RF, Dahle R, Danielsson K et al. (2022)
    Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants
    NPJ Vaccines, 7 (1), 174
    DOI 10.1038/s41541-022-00586-7, PubMed 36585405
11. Vaksdal HH, Grødeland G (2022)
    [Efficacy of three doses of COVID-19 vaccine]
    Tidsskr Nor Laegeforen, 142 (5)
    DOI 10.4045/tidsskr.22.0096, PubMed 35324133

Publications 2021

1. Andersen TK, Bodin J, Oftung F, Bogen B, Mjaaland S, Grødeland G (2021)
   Pandemic Preparedness Against Influenza: DNA Vaccine for Rapid Relief
   Front Immunol, 12, 747032
   DOI 10.3389/fimmu.2021.747032, PubMed 34691056
2. Andersen TK, Grødeland G (2021)
   [The vaccines can keep up with the SARS-CoV-2 mutations]
   Tidsskr Nor Laegeforen, 141 (3)
   DOI 10.4045/tidsskr.21.0080, PubMed 33624975
3. Ianevski A, Yao R, Lysvand H, Grødeland G, Legrand N, Oksenych V, Zusinaite E, Tenson T, Bjørås M, Kainov DE (2021)
   Nafamostat-Interferon-α Combination Suppresses SARS-CoV-2 Infection In Vitro and In Vivo by Cooperatively Targeting Host TMPRSS2
   Viruses, 13 (9)
   DOI 10.3390/v13091768, PubMed 34578348
4. Ianevski A, Yao R, Zusinaite E, Lello LS, Wang S, Jo E, Yang J, Ravlo E, Wang W, Lysvand H, Løseth K, Oksenych V, Tenson T, Windisch MP, Poranen MM, Nieminen AI, Nordbø SA, Fenstad MH, Grødeland G, Aukrust P, Trøseid M, Kantele A, Lastauskienė E, Vitkauskienė A, Legrand N et al. (2021)
   Synergistic Interferon-Alpha-Based Combinations for Treatment of SARS-CoV-2 and Other Viral Infections
   Viruses, 13 (12)
   DOI 10.3390/v13122489, PubMed 34960758
5. Jyssum I, Kared H, Tran TT, Tveter AT, Provan SA, Sexton J, Jørgensen KK, Jahnsen J, Kro GB, Warren DJ, Vaage EB, Kvien TK, Nissen-Meyer LH, Anderson AM, Grødeland G, Haavardsholm EA, Vaage JT, Mjaaland S, Syversen SW, Lund-Johansen F, Munthe LA, Goll GL (2021)
   Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study
   Lancet Rheumatol, 4 (3), e177-e187
   DOI 10.1016/S2665-9913(21)00394-5, PubMed 34977602
6. Nguyen D, Simmonds P, Steenhuis M, Wouters E, Desmecht D, Garigliany M, Romano M, Barbezange C, Maes P, Van Holm B, Mendoza J, Oyonarte S, Fomsgaard A, Lassaunière R, Zusinaite E, Resman Rus K, Avšič-Županc T, Reimerink JH, Brouwer F, Hoogerwerf M, Reusken CB, Grodeland G, Le Cam S, Gallian P, Amroun A et al. (2021)
   SARS-CoV-2 neutralising antibody testing in Europe: towards harmonisation of neutralising antibody titres for better use of convalescent plasma and comparability of trial data
   Euro Surveill, 26 (27)
   DOI 10.2807/1560-7917.ES.2021.26.27.2100568, PubMed 34240697
7. Vaksdal HH, Grødeland G (2021)
   [How effective is the COVID-19 vaccine for older persons?]
   Tidsskr Nor Laegeforen, 141 (18)
   DOI 10.4045/tidsskr.21.0748, PubMed 34911279
8. Zhou F, Hansen L, Pedersen G, Grødeland G, Cox R (2021)
   Matrix M Adjuvanted H5N1 Vaccine Elicits Broadly Neutralizing Antibodies and Neuraminidase Inhibiting Antibodies in Humans That Correlate With In Vivo Protection
   Front Immunol, 12, 747774
   DOI 10.3389/fimmu.2021.747774, PubMed 34887855

Publications 2020

1. Grødeland G, Baranowska-Hustad M, Abadejos J, Blane TR, Teijaro J, Nemazee D, Bogen B (2020)
   Induction of Cross-Reactive and Protective Antibody Responses After DNA Vaccination With MHCII-Targeted Stem Domain From Influenza Hemagglutinin
   Front Immunol, 11, 431
   DOI 10.3389/fimmu.2020.00431, PubMed 32269566
2. Taxt AM, Grødeland G, Lind A, Müller F (2020)
   Status of COVID-19 vaccine development
   Tidsskr Nor Laegeforen, 140 (13)
   DOI 10.4045/tidsskr.20.0676, PubMed 32998488

Publications 2019

1. Andersen TK, Huszthy PC, Gopalakrishnan RP, Jacobsen JT, Fauskanger M, Tveita AA, Grødeland G, Bogen B (2019)
   Enhanced germinal center reaction by targeting vaccine antigen to major histocompatibility complex class II molecules
   NPJ Vaccines, 4, 9
   DOI 10.1038/s41541-019-0101-0, PubMed 30775000
2. Grodeland G, Fossum E, Bogen B (2019)
   Targeting of HA to chemokine receptors induces strong and cross-reactive T cell responses after DNA vaccination in pigs
   Vaccine, 38 (6), 1280-1285
   DOI 10.1016/j.vaccine.2019.11.084, PubMed 31836256
3. Mooij P, Grødeland G, Koopman G, Andersen TK, Mortier D, Nieuwenhuis IG, Verschoor EJ, Fagrouch Z, Bogers WM, Bogen B (2019)
   Needle-free delivery of DNA: Targeting of hemagglutinin to MHC class II molecules protects rhesus macaques against H1N1 influenza
   Vaccine, 37 (6), 817-826
   DOI 10.1016/j.vaccine.2018.12.049, PubMed 30638800

Publications 2018

1. Anderson AM, Baranowska-Hustad M, Braathen R, Grodeland G, Bogen B (2018)
   Simultaneous Targeting of Multiple Hemagglutinins to APCs for Induction of Broad Immunity against Influenza
   J Immunol, 200 (6), 2057-2066
   DOI 10.4049/jimmunol.1701088, PubMed 29427414
2. Braathen R, Spång HCL, Lindeberg MM, Fossum E, Grødeland G, Fredriksen AB, Bogen B (2018)
   The Magnitude and IgG Subclass of Antibodies Elicited by Targeted DNA Vaccines Are Influenced by Specificity for APC Surface Molecules
   Immunohorizons, 2 (1), 38-53
   DOI 10.4049/immunohorizons.1700038, PubMed 31022690

Publications 2017

1. Andersen TK, Zhou F, Cox R, Bogen B, Grødeland G (2017)
   A DNA Vaccine That Targets Hemagglutinin to Antigen-Presenting Cells Protects Mice against H7 Influenza
   J Virol, 91 (23)
   DOI 10.1128/JVI.01340-17, PubMed 28931687

Publications 2016

1. Grodeland G, Fredriksen AB, Løset GÅ, Vikse E, Fugger L, Bogen B (2016)
   Antigen Targeting to Human HLA Class II Molecules Increases Efficacy of DNA Vaccination
   J Immunol, 197 (9), 3575-3585
   DOI 10.4049/jimmunol.1600893, PubMed 27671110
2. Lambert L, Kinnear E, McDonald JU, Grodeland G, Bogen B, Stubsrud E, Lindeberg MM, Fredriksen AB, Tregoning JS (2016)
   DNA Vaccines Encoding Antigen Targeted to MHC Class II Induce Influenza-Specific CD8(+) T Cell Responses, Enabling Faster Resolution of Influenza Disease
   Front Immunol, 7, 321
   DOI 10.3389/fimmu.2016.00321, PubMed 27602032

Publications 2015

1. Baranowska M, Hauge AG, Hoornaert C, Bogen B, Grødeland G (2015)
   Targeting of nucleoprotein to chemokine receptors by DNA vaccination results in increased CD8(+)-mediated cross protection against influenza
   Vaccine, 33 (49), 6988-96
   DOI 10.1016/j.vaccine.2015.08.094, PubMed 26387432
2. Grødeland G, Bogen B (2015)
   Efficient vaccine against pandemic influenza: combining DNA vaccination and targeted delivery to MHC class II molecules
   Expert Rev Vaccines, 14 (6), 805-14
   DOI 10.1586/14760584.2015.1029919, PubMed 25818107
3. Grødeland G, Fossum E, Bogen B (2015)
   Polarizing T and B Cell Responses by APC-Targeted Subunit Vaccines
   Front Immunol, 6, 367
   DOI 10.3389/fimmu.2015.00367, PubMed 26257735

Publications 2014

1. Fossum E, Grødeland G, Terhorst D, Tveita AA, Vikse E, Mjaaland S, Henri S, Malissen B, Bogen B (2014)
   Vaccine molecules targeting Xcr1 on cross-presenting DCs induce protective CD8+ T-cell responses against influenza virus
   Eur J Immunol, 45 (2), 624-35
   DOI 10.1002/eji.201445080, PubMed 25410055

Publications 2013

1. Grodeland G, Mjaaland S, Roux KH, Fredriksen AB, Bogen B (2013)
   DNA vaccine that targets hemagglutinin to MHC class II molecules rapidly induces antibody-mediated protection against influenza
   J Immunol, 191 (6), 3221-31
   DOI 10.4049/jimmunol.1300504, PubMed 23956431
2. Grødeland G, Mjaaland S, Tunheim G, Fredriksen AB, Bogen B (2013)
   The specificity of targeted vaccines for APC surface molecules influences the immune response phenotype
   PLoS One, 8 (11), e80008
   DOI 10.1371/journal.pone.0080008, PubMed 24244595

Publications 2010

1. Ruffini PA, Grødeland G, Fredriksen AB, Bogen B (2010)
   Human chemokine MIP1α increases efficiency of targeted DNA fusion vaccines
   Vaccine, 29 (2), 191-9
   DOI 10.1016/j.vaccine.2010.10.057, PubMed 21055498

Publications 2009

1. Huang TS, Grodeland G, Sleire L, Wang MY, Kvalheim G, Laerum OD (2009)
   Induction of circadian rhythm in cultured human mesenchymal stem cells by serum shock and cAMP analogs in vitro
   Chronobiol Int, 26 (2), 242-57
   DOI 10.1080/07420520902766025, PubMed 19212839